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Background/Aims: Acute pancreatitis is a common compli-
cation of endoscopic retrograde cholangiopancreatography 
(ERCP). Only a few pharmacologic agents have been shown 
to have potential efficacy for the prophylactic treatment of 
post-ERCP pancreatitis (PEP). The aim of this study was to 
determine whether prophylactic gabexate and ulinastatin 
can decrease the incidence of PEP. Methods: From Janu-
ary 2005 to April 2010, 1,679 patients undergoing ERCP 
treatment were consecutively enrolled in the study. After 
selective exclusion, a total of 1,480 patients were included 
in the analysis. The patients were separated into 3 groups 
according to the prophylactic administration of gabexate 
(593 patients), ulinastatin (229 patients), or saline solution 
(658 patients) and analyzed retrospectively. The primary 
outcome measurements were the incidence of pancreatitis 
and hyperamylasemia. Results: PEP occurred in 21 of the 
593 (3.5%) patients who received gabexate, 16 of the 229 
(7.0%) patients who received ulinastatin, and 48 of the 658 
(7.3%) patients who received a saline solution. The incidence 
of PEP was signiﬁ  cantly different between the gabexate and 
ulinastatin or saline solution groups (p<0.05). Conclusions: 
Gabexate prophylaxis is effective in preventing PEP. However, 
there is no difference in the beneﬁ  cial effects of the prophy-
lactic administration of ulinastatin and a saline solution. (Gut 
Liver 2012;6:256-261)
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INTRODUCTION
Acute pancreatitis is the most common complication of endo-
scopic retrograde cholangiopancreatography (ERCP), it is most 
often clinically mild or moderate in severity but in about 10% 
of cases it is severe and potentially fatal.
1 Despite improvements 
in technology and more experience in ERCP, the incidence of 
post-ERCP pancreatitis (PEP) has not yet decreased significantly. 
PEP is associated with substantial morbidity and even mortal-
ity. Although the pathophysiology of PEP is not completely 
understood, numerous factors, including hydrostatic injury, 
obstruction of pancreatic juice outflow, thermal injury from 
electrocautery current, and chemical or allergic injury, can act 
independently or in combination to induce PEP.
2 
The pharmacologic agents that have been proposed and 
tested for prophylaxis of PEP are various, but only a few have 
been shown to have any proven efficacy. In a recent European 
Society of Gastrointestinal Endoscopy guideline for prophylaxis 
of PEP
1 non-steroidal anti-inflammatory drugs are the only 
drugs with proven efficacy. Glyceryl trinitrate (nitroglycerin), 
ceftazidime, somatostatin, octreotide, and antiprotease drugs are 
possibly effective drugs. However, glucocorticoids; drugs reduc-
ing pressure on the sphincter of Oddi other than nitroglycerin, 
such as botulinum toxin, epinephrine, lidocaine, and nifedipine; 
antioxidant drugs such as allopurinol, n-acetylcysteine, and 
heparin; and interleukin-10 were proven ineffective.
1 
Antiproteases, which have been clinically used to manage 
acute pancreatitis, would theoretically reduce pancreatic injury 
after ERCP because activation of proteolytic enzymes is con-
sidered to play an important role in the pathogenesis of PEP. Yoo YW, et al: Use of Gabexate and Ulinastatin for the Prevention of Post-ERCP Pancreatitis  257
Currently, three antiproteases; gabexate mesylate, ulinastatin, 
and nafamostat have been evaluated for their prophylactic ef-
ficacy against PEP in prospective randomized controlled trials.
2-6 
However, most results are controversial, prophylaxis against 
PEP with these drugs has been carried out using various drug 
dosages, and no adequate study has been performed to identify 
the optimal method or dosage of administration of the drugs. 
The present study was designed to evaluate retrospectively 
the efficacy of intravenous gabexate mesylate and ulinastatin in 
preventing PEP and hyperamylasemia in comparison with con-
trol group. 
MATERIALS AND METHODS
1. Patients
From January 2005 to April 2010, 1,679 patients underwent 
ERCP in the gastrointestinal endoscopy unit of Eulji University 
Hospital (a tertiary referral center) were consecutively enrolled. 
Exclusion criteria were as follows: age <19 years, previous 
sphincterotomy, acute pancreatitis before ERCP, and pregnancy. 
After selective exclusion, a total of 1,480 patients were included 
in the analysis. Patients were separated into 3 groups according 
to the prophylactic administration of a continuous intravenous 
infusion of gabexate mesylate (400 mg, 593 patients, group A), 
ulinastatin (150,000 units, 229 patients, group B), or saline solu-
tion (658 patients, group C), and analyzed retrospectively (Fig. 1). 
Written informed consent was obtained from all patients. This 
study was approved by the Institutional Review Board of our 
hospital.
2. Administration of gabexate mesylate or ulinastatin, and 
follow-up
Four hundred milligram of gabexate mesylate (Foy; Dong-A 
Pharmaceutical, Seoul, Korea) or 150,000 units of ulinastatin 
(Ulistin; Hanlim Pharmacy, Seoul, Korea) was dissolved in 500 
mL of 5% dextrose solution and administered by continuous in-
travenous infusion beginning 30 minutes before ERCP and con-
tinuing for 24 hours afterwards. In group C, 500 mL of saline 
solution was administered by continuous infusion during the 
same time as control (Fig. 1). Benzodiazepines, anti-spasmodic 
agents, and non-narcotic analgesics, alone or in combination, 
were administered routinely before the procedure. Therapy with 
antibiotics and analgesics was allowed to be continued. Two 
senior endoscopists directly performed all the procedures using 
side-viewing endoscopes (JF-240, JF-260V, and TJF-240; Olym-
pus Optical Co., Ltd., Tokyo, Japan). Serum amylase and lipase 
levels were checked before ERCP, 4 and 24 hours after ERCP, 
and when clinically indicated. The presence of abdominal pain 
attributable to the pancreas and the use and type of analgesic 
therapy at those times were evaluated. The primary outcome 
measurements were the incidence of pancreatitis and hyper-
amylasemia.
3. Deﬁ  nitions
The definition of PEP was based on the consensus criteria.
7 It 
was defined as the following: a newly developed or increased 
abdominal pain within 24 hours after ERCP requiring analgesic 
agents, and the elevation of serum amylase and/or lipase level 
Fig. 1. Study flow diagram.
ERCP, endoscopic retrograde cho-
langiopancreatography; EST, endo-
scopic sphincterotomy; PD, pancre-
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at least 3 times the normal upper limit about 24 hours after the 
procedure. The severity was graded mild when hospitalization 
lasted 2 to 3 days, moderate when it lasted 4 to 10 days, and 
severe when it was prolonged for more than 10 days or any of 
the following complications occurred: hemorrhagic pancreatitis, 
pancreatic necrosis, pancreatic pseudocyst, or a need for per-
cutaneous drainage or surgery. Hyperamylasemia was defined 
as elevation of serum amylase levels to more than 3 times the 
normal upper limit at 4 and/or 24 hours after the ERCP without 
other symptoms. Visualization of the entire pancreatic duct by 
contrast injection was regarded as pancreatic injection. Precut 
sphincterotomy was performed at the periampullary area, and 
infundibulotomy was not performed. Difficult cannulation, 
based on the number of attempts on the papilla with a can-
nulating instrument, was defined as more than 10 attempts 
occurred, or failure of cannulation after 10 minutes.
8 Failed 
selective bile duct cannulation was categorized into the “difficult 
cannulation” group.
4. Statistical analysis
The χ
2 and Fisher exact test were used for comparisons of 
categorical data. All continuous data values were expressed as 
means±SD. Differences in variance of the data between the 3 
groups were examined by repeated measures analysis of vari-
ance and Bonferroni’s method was employed for within subjects 
comparisons. Differences in the mean values were examined by 
Student’s t-test. A p<0.05 indicated statistical significance. Sta-
tistical calculations were performed with SPSS version 12.0 for 
Windows (SPSS Inc., Chicago, IL, USA).
RESULTS
Of the 1,679 total patients who were enrolled for the study, 
199 were excluded from the final analysis for the following 
reasons: age <19 years (5 patients), previous sphincterotomy 
(90 patients), acute pancreatitis before ERCP (97 patients), preg-
nancy (3 patients), and absence of post-ERCP evaluation (4 
patients). The “previous sphincterotomy” group included any 
patients with a history of a biliary sphincterotomy, biliary stent 
removal or replacement, or confirmation of biliary clearance 
after stone extraction.
Ultimately, data from 1,480 patients (gabexate mesylate 
group, 593; ulinastatin group, 229; control group, 658) were 
analyzed. The mean age was 65.19±15.23 years, and 691 (46.7%) 
patients were women. The most common indication for ERCP 
was choledocholithiasis (59.1%, 874/1,480), followed by cho-
lecystolithiasis (10.9%, 162/1,480), cholangiocarcinoma (9.9%, 
146/1,480), and pancreatic cancer (5.2%, 77/1,480). The gabex-
ate mesylate, ulinastatin, and control groups were similar in 
respect to patient demographics and the common distribution 
of indications for the procedure (Table 1). Patients were clas-
sified as high risk if they had any of the high-risk parameters 
Table 1. Baseline Characteristics of Patients in the Gabexate Mesylate, Ulinastatin, and Control Groups
Characteristic
Group A Group B Group C
p-value
Gabexate (n=593) Ulinastatin (n=229) Control (n=658)
Gender
   Male 303 (51.1) 128 (55.9) 358 (54.4) NS
   Female 290 (48.9) 101 (44.1) 300 (45.6) NS
Age, mean±SD 65.5±15.2 65.6±15.4 64.7±15.2 NS
Main indication for ERCP
   Choledocholithiasis 350 (59.0) 144 (62.9) 380 (57.8) NS
   Cholecystolithiasis 54 (9.1)  27 (11.8)  81 (12.3) NS
   Cholangiocarcinoma 54 (9.1) 18 (7.9)  74 (11.2) NS
   Pancreatic cancer 33 (5.6)  7 (3.1) 37 (5.6) NS
   Miscellaneous bile duct disease  69 (11.6)  24 (10.5)  75 (11.4) NS
   Miscellaneous pancreatic duct disease 33 (5.6)  9 (3.9) 11 (1.7) NS
High risk group 102 (17.2)  44 (19.2) 106 (16.1) NS
   Age <40 yr 46 (7.8)  25 (10.9) 54 (8.2) NS
   Prior pancreatitis 19 (3.2)  6 (2.6)  9 (1.4) NS
   Suspected SOD  3 (0.5)  0 (0.0)  1 (0.2) NS
   Difficult cannulation 24 (4.0) 15 (6.6) 26 (4.0) NS
   Precut sphincterotomy 10 (1.7)  6 (2.6) 16 (2.4) NS
Data are presented as mean±SD or number (%).
NS, not significant; ERCP, endoscopic retrograde cholangiopancreatography; SOD, sphincter of Oddi dysfunction.Yoo YW, et al: Use of Gabexate and Ulinastatin for the Prevention of Post-ERCP Pancreatitis  259
identified by Freeman and Guda,
9 such as young age, suspected 
sphincter of Oddi dysfunction, prior pancreatitis, difficult can-
nulation, or precut sphincterotomy. Of the total 252 high-risk 
patients, 102 were in the gabexate mesylate group, 44 were 
in the ulinastatin group, and 106 were in the control group. 
The incidence of high-risk factors for PEP was similar in the 3 
groups (Table 1).
Endoscopic sphincterotomy was performed in about 63.8% 
(944/1,480) of the therapeutic endoscopic procedures, with no 
significant differences among the 3 groups. Also similar were 
the rates of patients with bile duct cannulation failure, precut 
sphincterotomy, endoscopic sphincterotomy and/or stone ex-
traction, endoscopic papillary balloon dilation (EPBD) and/or 
stone extraction, stricture dilation, endoscopic retrograde bili-
ary drainage, and endoscopic papillectomy (Table 2). However, 
EPBD was performed more in the ulinastatin group (19.7%, 
45/229) than in the gabexate mesylate group (10.8%, 64/593) 
and control group (10.7%, 70/658), and this difference was sig-
nificant (p=0.001). 
1. Post-ERCP hyperamylasemia and PEP
The overall incidence of post-ERCP hyperamylasemia was 
12.9% (192/1,480). There was no significant difference in the 
rate of post-ERCP hyperamylasemia between the gabexate me-
sylate (12.3%, 73/593), ulinastatin (10.9%, 25/229), and control 
(14.3%, 94/658) groups (p=0.351). PEP was developed in 5.7% 
(85/1,480) of the patients. There was a significant difference in 
the rate of PEP between the gabexate mesylate (3.5%, 21/593), 
ulinastatin (7.0%, 16/229), and control (7.3%, 48/658) groups 
(p=0.012). Moreover, patients who were given gabexate mesyl-
ate (3.5%) had lower rates of PEP than those who were given 
ulinastatin (7.0%), and this difference was statistically signifi-
cant (p=0.039). Among the 85 patients who developed pancre-
atitis, 24 (28.3%) had moderate to severe pancreatitis (3 patients 
in the gabexate mesylate group, 6 in the ulinastatin group, and 
15 in the control group). There was a significant difference in 
the rate of moderate to severe PEP between the gabexate mesyl-
ate (0.5%, 3/593), ulinastatin (2.6%, 6/229), and control(2.3%, 
15/658) groups (p=0.020) (Table 3). 
2. Side effects
None of the patients experienced any adverse effects related 
to gabexate mesylate, ulinastatin or saline solution administra-
tion, such as shock, itching, rash, nausea, vomiting, or neutro-
Table 2. Therapeutic Procedures for Each Group 
Variable
Group A Group B Group C
p-value
Gabexate (n=593) Ulinastatin (n=229) Control (n=658)
Failure of BD cannulation 10 (1.7) 4 (1.7) 20 (3.0) NS
Precut sphincterotomy 10 (1.7) 6 (2.6) 16 (2.4) NS
EST 368 (62.1) 156 (68.1) 420 (63.8) NS
   EST with stone extraction 236 (39.8) 107 (46.7) 255 (38.8) NS
EPBD  64 (10.8) 45 (19.7)  70 (10.7)   0.001
   EPBD with stone extraction 54 (9.1) 41 (17.9) 60 (9.1) <0.001
   EPBD with stricture dilatation 10 (1.7) 4 (1.7) 10 (1.5) NS
Biliary drainage 244 (41.1) 73 (31.9) 272 (41.3) NS
Endoscopic papillectomy  2 (0.3) 2 (0.9)  1 (0.2) NS
Data are presented as number (%).
BD, bile duct; NS, not significant; EST, endoscopic sphincterotomy; EPBD, endoscopic papillary balloon dilatation.
Table 3. Incidence of Post-ERCP Hyperamylasemia and Post-ERCP Pancreatitis in Each Group
Variable
Group A Group B Group C
p-value
Gabexate (n=593) Ulinastatin (n=229) Control (n=658)
Hyperamylasemia 73 (12.3) 25 (10.9) 94 (14.3) NS
Incidence of post-ERCP pancreatitis 21 (3.5)*
,† 16 (7.0)* 48 (7.3)
† 0.012
Severity of post-ERCP pancreatitis
   Mild 18 (3.0) 10 (4.4) 33 (5.0) NS
   Moderate to severe  3 (0.5)
‡,§  6 (2.6)
‡  15 (2.3)
§ 0.020
Data are presented as number (%).
NS, not significant; ERCP, endoscopic retrograde cholangiopancreatography.
*Group A vs group B, p=0.039; 
†Group A vs group C, p=0.004; 
‡Group A vs group B, p=0.017; 
§Group A vs group C, p=0.009.260  Gut and Liver, Vol. 6, No. 2, April 2012
penia.
DISCUSSION
ERCP and sphincterotomy are essential procedures for man-
aging pancreaticobiliary disease. Among the complications of 
ERCP, acute pancreatitis is the most frequent and troublesome. 
The pathogenesis of PEP is not well understood but is most like-
ly multifactorial. Hypothesized mechanisms of pancreatic injury 
include mechanical, chemical, hydrostatic, thermal, enzymatic, 
microbiologic, allergic, immunologic reactions, etc. On the basis 
of the hypothesis, various attempts have been made to prevent 
PEP, such as change of technique, patient selection, pancreatic 
stenting, and pharmacologic prophylaxis.
10 
Many pharmacologic agents of different types have been 
used to prevent PEP on the assumption that they may pharma-
cologically inhibit one or more of the aforementioned factors 
associated with pancreatic damage. Irrespective of the etiology 
of acute pancreatitis, the activation of proteolytic enzymes, 
starting with trypsinogen activation to trypsin in pancreatic 
acinar cells, has been considered to play an initial role in the 
pathogenesis of pancreatitis. Trypsin would subsequently trigger 
the activation of other enzymes and the inflammatory cascade. 
Antiproteases, which have been used to manage acute pancre-
atitis in routine clinical settings in some countries,
11 may be 
theoretically useful for preventing PEP. Prevention of PEP with 
antiproteases, gabexate, or ulinastatin, has been evaluated in 
several studies. Some studies clearly demonstrated that gabexate 
mesylate or ulinastatin is effective in reducing the incidence of 
PEP,
2,4,8,12,13 other studies did not find any benefit in administrat-
ing either drug.
3,5,12 Compared with gabexate mesylate, ulina-
statin has a stronger inhibitory effect on pancreatic enzymes in 
various experimental models of pancreatitis.
14 To date, however, 
very a few reports comparing the efficacy of gabexate mesylate 
and ulinastatin with regard to the prevention of PEP have been 
published. Two Japanese clinical trials compared gabexate me-
sylate with ulinastatin administered before and after ERCP, and 
the rates of PEP were not significantly different.
13,15 
In our study, in a consecutive series of hospitalized patients 
who underwent ERCP, we compared the effects of a 24-hour 
continuous intravenous drip infusion of either 400 mg of ga-
bexate mesylate or 150,000 units of ulinastatin, beginning 30 
minutes before the ERCP. We found that gabexate mesylate 
prophylaxis before and after ERCP was effective in preventing 
PEP. However, prophylactic administration of ulinastatin did 
not show a beneficial efficacy to prevent PEP. Recent systemic 
review reported ulinastatin shows to be of value on preventing 
PEP and hyperamylasemia for patients in average risk, when 
given intravenously at a dose of not less than 150,000 unit, 
just before ERCP.
16 In our study, we designed to 150,000 unit of 
ulinastatin infusion duration for 24 hours start from 30 minutes 
before ERCP. Considering duration of infusion and difference of 
infusion dose intensity, it could make different result from other 
previous studies.
In general, because of its short half-life, gabexate should be 
administered continuously for a long period of time (greater 
than 12 hours) and at a relatively high dose (greater than 500 
mg to 1 g) in order to prevent pancreatitis.
2,8,17 In the present 
study, we used a relatively low dose of gabexate mesylate (400 
mg) compared with the previous studies (500 mg or 1 g). In Ko-
rea, the cost of 400 mg of gabexate mesylate is about US $18, 
whereas 150,000 units of ulinastatin is US $44. And the cost of 
continuous infusion of 0.75 mg and 3 mg of somatostatin, an-
other widely evaluated and possibly effective drug, is about US 
$40 and US $109, respectively. Thus, gabexate mesylate is more 
cost effective than either alternative drug. The important results 
of the present study show that a 24-hour infusion of 400 mg of 
gabexate mesylate at a relatively lower dose than in previous 
studies significantly reduced the incidence of PEP.
The increasing risk of pancreatitis after EPBD remains a 
controversial but serious issue. In an American study,
18 the inci-
dence of pancreatitis was unacceptably high in an EPBD group 
(15.4%, 18/117), and 2 of 6 patients with severe pancreatitis 
died. This unfortunate result is in striking contrast to the results 
of an uncontrolled study and a randomized controlled study; 
no fatal pancreatitis was observed after EPBD in a total of more 
than 600 patients reported.
19,20 In our current study, although 
EPBD is not associated with a risk for PEP (odds ratio, 0.69; 
95% confidence interval, 0.09 to 5.36; p=0.722) on univari-
ated analysis, EPBD was performed significantly more in the 
ulinastatin group (19.7%, 45/229) than in the gabexate mesylate 
group (10.8%, 64/593) and control group (10.7%, 70/658). This 
difference may have an effect on the incidence of PEP. 
The current study has some limitations. The 3 groups were 
not randomized, the number of patients with ulinastatin pro-
phylaxis was relatively small compared with other groups, and 
the analysis was retrospective. In our center, we had changed 
strategy to premedication for prophylaxis of PEP. It was gabex-
ate mesylate in January 2005 to December 2006, no prophylac-
tic medication in January 2007 to August 2009, and ulinastatin 
in September 2009 to April 2010. So variation on number of 
groups is a reflection of changes on number of patients at our 
center. The study was done in a single large tertiary care cen-
ter. Most patients needed therapeutic intervention, including 
endoscopic sphincterotomy or EPBD, and were admitted via the 
emergency department because of acute cholangitis or severe 
abdominal pain. Thus, we performed ERCP on an inpatient ba-
sis, and continuous intravenous infusion of gabexate mesylate 
or ulinastatin could be started before the procedure and con-
tinued 24 hours thereafter. Thus, it may be impractical to use 
gabexate mesylate or ulinastatin during outpatient procedures 
in elective cases.
In conclusion, 24-hour infusion of 400 mg of gabexate 
mesylate at a relatively low dose significantly reduced the in-Yoo YW, et al: Use of Gabexate and Ulinastatin for the Prevention of Post-ERCP Pancreatitis  261
cidence of PEP. However, prophylactic administration of ulina-
statin, compared with gabexate mesylate and control group, did 
not show a beneficial influence on the incidence of PEP. Further 
prospective randomized large multicenter studies are needed. 
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